IIBR-100

NRx Pharmaceuticals Announces Leadership Transition

Retrieved on: 
Wednesday, March 9, 2022
Nasdaq, Master, Development, Trial of the century, COVID, ASIB, MPH, Company, Interim, Deutsche Bank, Eli Lilly, Partnership, Biology, FDA, Breakthrough therapy, Director, International Management Institute, New Delhi, Thunderbird School of Global Management, Lists of diseases, Health, Board, IIBR-100, Israel Institute for Biological Research, Patient, Thunderbird, Reading, Dark Enlightenment, US Foods, Aviptadil, Degenerative disease, Human services, Biomedical Advanced Research and Development Authority, Head, COVID-19, Psychiatry, Letter, Pfizer, Food, Goal, Board of directors, Vaccine, CEO, Fast Track, Management, Pharmaceutical industry, Critical, MD, Behavior

RADNOR, Pa., March 8, 2022 /PRNewswire/ --NRx Pharmaceuticals (Nasdaq: NRXP) ("NRx" or the "Company"), a clinical-stage, biopharmaceutical company, today announced that Jonathan Javitt, MD, MPH, has retired as Chief Executive Officer effective immediately.

Key Points: 
  • RADNOR, Pa., March 8, 2022 /PRNewswire/ --NRx Pharmaceuticals (Nasdaq: NRXP) ("NRx" or the "Company"), a clinical-stage, biopharmaceutical company, today announced that Jonathan Javitt, MD, MPH, has retired as Chief Executive Officer effective immediately.
  • As part of the transition, Dr. Javitt will assume a new consulting role as the Company's Chief Scientist, where he will continue to help advance the Company's pipeline.
  • Prior to joining NRx, Besthof served as Vice President of Global Commercial Development for Neuroscience & Pain at Pfizer.
  • NRx Pharmaceuticals (Nasdaq: NRXP) draws on decades of collective, scientific and drug-development experience to bring improved health to patients.

NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine

Retrieved on: 
Friday, February 11, 2022
Dark Enlightenment, MPH, Hebrew language, Lilly, Biology, Pandemic, Goal, Technology transfer, Technology, Engineering, Health, Company, RNA transfection, VSV, J&J, Biotechnology, US Foods, Human services, Biomedical Advanced Research and Development Authority, COVID-19, Hope, Development, Cattle, Breakthrough therapy, Fast Track, GLOBE, JD, Patient, Food, Human, Immunity, Environment, Novartis, Omicron, ASPE, Letter, FDA, BARDA, Israel Institute for Biological Research, Trial of the century, Vaccine, Pharmaceutical industry, Teva, Pfizer, IIBR-100, Allergan, MD

The technology of the vaccine is engineering of spike protein on a VSV virus, that is infectious mainly in cattle.

Key Points: 
  • The technology of the vaccine is engineering of spike protein on a VSV virus, that is infectious mainly in cattle.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.
  • The Company is developing the BriLife Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense.
  • The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron Variant

Retrieved on: 
Tuesday, January 11, 2022
Muscle, Research, Biology, Biotechnology, Patient, NASDAQ, Novartis, Development, JD, Israel Institute for Biological Research, US Foods, Biomedical Advanced Research and Development Authority, MPH, Vaccination, Conference, National, COVID-19, National Security Advisor (United States), IIBR-100, Company, Food, FDA, News, Dark Enlightenment, J&J, Vaccine, Hope, Fast Track, ASPE, Human services, United States Army, BARDA, Breakthrough therapy, Review, Skin, Angiotensin-converting enzyme 2, RNA transfection, ACE2, Lilly, Letter, CEO, GLOBE, Goal, Omicron, Pharmaceutical industry, Delta, Allergan, Health, Teva, Pfizer, MD

Last week, NRx met with experts from the Israel Institute for Biological Research (IIBR) to review data and research related to the ability of the BriLife vaccine to induce neutralizing antibodies against the Omicron variant.

Key Points: 
  • Last week, NRx met with experts from the Israel Institute for Biological Research (IIBR) to review data and research related to the ability of the BriLife vaccine to induce neutralizing antibodies against the Omicron variant.
  • Based on the preliminary findings, NRx is currently designing a phase 2b/3 study of the BriLife vaccine as a booster to protect against COVID-19 variants of concern including the Omicron variant.
  • In further news, the Israel Ministry of Health recently approved a study investigating the NanoPass MicronJet intradermal injection system for the BriLife vaccine.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.

NRx Pharmaceuticals to Announce New Details for Planned Investigational BriLife™ COVID-19 Vaccine

Retrieved on: 
Friday, January 7, 2022
COVID-19, Novartis, Review, Goal, J&J, Institutional review board, Israel Institute for Biological Research, NASDAQ, FDA, MPH, Dark Enlightenment, Biomedical Advanced Research and Development Authority, National, Biotechnology, National Security Advisor (United States), JD, Fast Track, Letter, Biology, Lilly, BARDA, Board, Clinical trial, Development, Food, Omicron, Company, Patient, United States Army, Conference, CEO, Health, GLOBE, Coronavirus, IIBR-100, US Foods, Breakthrough therapy, Human services, ASPE, Pharmaceutical industry, Teva, Pfizer, MD, Allergan, Delta

As the Omicron variant of the Coronavirus continues to surge, NRx has focused on whether the BriLife investigational vaccine is effective against this latest variant of COVID-19.

Key Points: 
  • As the Omicron variant of the Coronavirus continues to surge, NRx has focused on whether the BriLife investigational vaccine is effective against this latest variant of COVID-19.
  • Last month, our early data showed BriLife to be effective against the Delta variant, said Prof Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals.
  • We will provide preliminary findings and discuss enhancements to the planned clinical trials for the BriLife investigational vaccine at the upcoming HC Wainwright BioConnect Conference.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.

NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI® and BriLife COVID-19 Vaccine Trials

Retrieved on: 
Thursday, December 9, 2021
Dark Enlightenment, COVID-19, GLOBE, National, Health, ASPE, United States Army, Lilly, Novartis, National Security Advisor (United States), Fast Track, Safety, IIBR-100, Food, Patient, CEO, COVID, Lesya Ukrainka East European National University, Israel Institute for Biological Research, Emergency Use Authorization, JD, J&J, BARDA, Authorization, MPH, Biomedical Advanced Research and Development Authority, Biology, Breakthrough therapy, Human services, Development, Program, FDA, NASDAQ, Goal, Letter, US Foods, Central European, Pharmaceutical industry

Hungary will be the first European Nation to host a clinical trial site for the registrational phase 2b/3 trial of the BriLife COVID-19 vaccine.

Key Points: 
  • Hungary will be the first European Nation to host a clinical trial site for the registrational phase 2b/3 trial of the BriLife COVID-19 vaccine.
  • The NRx initiative in Hungary will be led by senior regulatory and academic medical leaders.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.
  • InJuly 2021, the Government ofIsraelawarded NRx the exclusive worldwide right to develop and market the BriLife COVID vaccine developed by the Israel Institute for Biological Research.

NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research

Retrieved on: 
Friday, November 26, 2021
Coronavirus, Company, National Security Advisor (United States), BARDA, JD, Immunity, GLOBE, Letter, Biotechnology, Development, Israel Institute for Biological Research, Human services, Food, N501Y, CEO, United States Army, COVID-19, Biomedical Advanced Research and Development Authority, National, Review, Biology, Health, MPH, Goal, J&J, Fast Track, FDA, Patient, Dark Enlightenment, US Foods, Randomized controlled trial, Breakthrough therapy, Acquisition, Novartis, Severe acute respiratory syndrome coronavirus 2, ASPE, IIBR-100, Manuscript, Lilly, Data monitoring committee, Antibody, NASDAQ, Vaccine, Pharmaceutical industry

A second group of blood samples (sera) were drawn from unvaccinated patients who contracted and recovered from Covid-19.

Key Points: 
  • A second group of blood samples (sera) were drawn from unvaccinated patients who contracted and recovered from Covid-19.
  • Those patients had antibodies against the wild-type Coronavirus but with a 3.8 fold reduction in immune response (neutralizing titers) to the Delta variant.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.
  • The Company is developing the BriLife Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israel Ministry of Defense.

NRx Pharmaceuticals Initiates Senior Level Finance and Business Initiatives with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife® COVID-19 Vaccine Production

Retrieved on: 
Friday, November 5, 2021
MPH, GMP, Lilly, Food, COVID-19, Innovation, Human services, Biology, Directorate, Fast Track, Novartis, BNP Paribas, BNP, United States Army, Technology, Biotechnology, Breakthrough therapy, Patient, FDA, Health, NASDAQ, Ministry, Goal, ASPE, Biomedical Advanced Research and Development Authority, Good manufacturing practice, National Security Advisor (United States), Government, J&J, US Foods, Letter, Solution, National, JD, Board, Company, Development, IIBR-100, Economy, Israel Institute for Biological Research, Dark Enlightenment, Vaccine, Pharmaceutical industry

NRx Luxembourg has been granted an operating company business license by the Luxembourg government and has established a commercial banking relationship with BNP Paribas (Luxembourg), managed by BNP's Head of Global Trade Solutions.

Key Points: 
  • NRx Luxembourg has been granted an operating company business license by the Luxembourg government and has established a commercial banking relationship with BNP Paribas (Luxembourg), managed by BNP's Head of Global Trade Solutions.
  • NRx is currently negotiating a comprehensive banking and finance solution in preparation for tech transfer, scale-up, and manufacture of the BriLife vaccine.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.
  • NRx is led by executives who have held senior roles at Allergan, J&J, Lilly, Novartis, Pfizer, and the US FDA.

NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Wednesday, September 8, 2021

RADNOR, Pa., Sept. 8, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.

Key Points: 
  • RADNOR, Pa., Sept. 8, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.
  • Available on demand beginning September 13, 2021 at 7 AM EST
    NRx Pharmaceuticals (NRx) ( www.nrxpharma.com ) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients.
  • NRx also has the BriLife vaccine for COVID-19 in clinical trials and holds the exclusive worldwide license to commercialize the vaccine.
  • NRx is led by executives who have held senior roles at Allergan, J&J, Lilly, Novartis, Pfizer, and the US FDA.

NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies

Retrieved on: 
Thursday, August 26, 2021
Cell death, VIP, ACE2, Blood, Fast Track, Human services, Food, Health, Hospital, Senior, Proning, Partnership, Aviptadil, Lung, Emergency Use Authorization, Medicine, ASPE, Biomedical Advanced Research and Development Authority, Cardinal Health, Vasoactive intestinal peptide, Lilly, MPH, US Foods, Enteroendocrine cell, General officer, Dark Enlightenment, Israel Institute for Biological Research, Coronavirus diseases, Letter, Critical, Nasdaq, EUA, IIBR-100, Biotechnology, Cardinal, Development, Goal, High-dependency unit, Novartis, FDA, United States Army, National, ATII, Strategic sourcing, Private Securities Litigation Reform Act, JD, J&J, Biology, Inflammation, Breathe Me, Patient, COVID-19, Breakthrough therapy, Pharmaceutical industry, Vaccine

This partnership creates an efficient and highly flexible logistics and distribution model for NRx.

Key Points: 
  • This partnership creates an efficient and highly flexible logistics and distribution model for NRx.
  • "This partnership creates an efficient and highly flexible logistics and distribution model for NRx.
  • Cardinal Health Specialty Pharmaceutical Distribution will serve as the exclusive distributor for ZYESAMI, providing broad access to hospitals for this needed medicine upon FDA authorization.
  • "Cardinal Health is pleased to ensure that COVID-19 patients get access to treatment in a timely and efficient manner."

NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

Retrieved on: 
Wednesday, August 18, 2021
Extracorporeal membrane oxygenation, VIP, National, Dark Enlightenment, Government, ASPE, Biomedical Advanced Research and Development Authority, Fast Track, Human services, Letter, Critical, Remdesivir, Review, Private Securities Litigation Reform Act, Food, Data monitoring committee, Health, JD, J&J, Lilly, Critical care, Biology, IIBR-100, Biotechnology, MPH, Development, NASDAQ, Safety, Goal, Patient, Novartis, Aviptadil, US Foods, Failure rate, National Security Advisor (United States), FDA, United States Army, Vasoactive intestinal peptide, COVID-19, Breakthrough therapy, Israel Institute for Biological Research, Pharmaceutical industry

The study's Data Safety Monitoring Board found no new safety concerns in the trial and recommended continued enrollment.

Key Points: 
  • The study's Data Safety Monitoring Board found no new safety concerns in the trial and recommended continued enrollment.
  • Study investigators are randomizing patients to receive one of four treatment regimens in addition to standard of care: both ZYESAMI and remdesivir, ZYESAMI and a placebo, remdesivir and placebo, or only placebo.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.